Triptorelin: The GnRH Agonist With Flare-Then-Suppression Pharmacology

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Triptorelin?

Triptorelin (also known as triptorelin pamoate or triptorelin acetate) is a synthetic analog of gonadotropin-releasing hormone (GnRH) classified as a GnRH agonist. It differs from native gonadorelin by a single amino acid substitution — the glycine at position 6 is replaced with D-tryptophan (D-Trp6). This seemingly minor modification dramatically alters the pharmacological profile: the D-amino acid substitution confers resistance to enzymatic degradation by endopeptidases, extending the biological half-life and transforming a short-acting physiological signal into a long-acting pharmaceutical agent.

Triptorelin belongs to the same class as other GnRH agonists including leuprolide (Lupron), goserelin (Zoladex), and nafarelin (Synarel). All share the fundamental pharmacological property of inducing gonadotropin suppression through continuous receptor stimulation — a paradoxical mechanism where a receptor agonist ultimately produces the functional equivalent of receptor blockade.

Property	Detail
Generic Name	Triptorelin (pamoate or acetate salt)
Brand Names	Trelstar (prostate cancer), Triptodur (precocious puberty), Decapeptyl
Structure	Decapeptide with D-Trp6 substitution
Molecular Weight	~1,311 Da (free base)
Mechanism	GnRH receptor agonist → downregulation → suppression
Available Formulations	1-month (3.75 mg), 3-month (11.25 mg), 6-month (22.5 mg) depot
Route	Intramuscular injection
FDA Status	Approved for prostate cancer and central precocious puberty

Mechanism of Action

The mechanism of triptorelin exemplifies one of the most elegant pharmacological paradoxes in endocrinology: how a receptor agonist can produce the functional equivalent of an antagonist through sustained activation.

Phase 1: The Flare (Days 1–7)

Upon initial administration, triptorelin binds and activates GnRH receptors on pituitary gonadotrophs, triggering an acute surge of LH and FSH release. This "flare" can increase testosterone levels in men by 50–100% above baseline and similarly elevate estradiol in women. In prostate cancer patients, this flare can transiently worsen symptoms — a clinically important consideration.

Phase 2: Downregulation (Days 7–21)

Continuous receptor occupancy triggers GnRH receptor internalization and degradation. The pituitary gonadotroph cells reduce surface GnRH receptor expression by 80–90%. Simultaneously, intracellular signaling pathways become desensitized. LH and FSH levels begin to fall.

Phase 3: Suppression (Day 21 onward)

With sustained treatment, gonadotropin levels fall to castrate or near-castrate levels. Testosterone in men typically drops below 50 ng/dL (the standard castrate threshold), and estradiol in women falls to postmenopausal levels. This chemical castration is maintained as long as the drug is continued and is reversible upon discontinuation.

Research and Clinical Applications

Prostate Cancer

The primary FDA-approved indication for triptorelin (as Trelstar) is the palliative treatment of advanced prostate cancer. By suppressing testosterone to castrate levels, triptorelin removes the androgenic stimulus for prostate cancer cell growth. This androgen deprivation therapy (ADT) remains a cornerstone of prostate cancer management for locally advanced and metastatic disease. Clinical trials have demonstrated that triptorelin achieves castrate testosterone levels in 90–95% of patients by day 29.

Central Precocious Puberty

Triptorelin (as Triptodur) is FDA-approved for the treatment of central precocious puberty (CPP) in children aged 2 years and older. By suppressing the premature activation of the HPG axis, triptorelin halts the progression of puberty, slowing bone age advancement and preserving adult height potential. The 6-month depot formulation is particularly convenient for pediatric patients.

Endometriosis and Uterine Fibroids

GnRH agonists including triptorelin are widely used in the management of endometriosis and uterine fibroids. By creating a hypoestrogenic state, triptorelin induces regression of estrogen-dependent endometrial implants and fibroids. Treatment duration is typically limited to 6 months due to concerns about bone mineral density loss associated with prolonged estrogen deprivation, though "add-back" therapy with low-dose estrogen/progestin can extend the treatment window.

IVF Protocols

In assisted reproduction, triptorelin is used in both long-protocol and short-protocol IVF cycles. In long protocols, triptorelin is started in the luteal phase of the preceding cycle to suppress the HPG axis before controlled ovarian stimulation. In short (flare) protocols, triptorelin is started early in the stimulation cycle to exploit the initial LH/FSH flare as an adjunct to gonadotropin stimulation.

Safety and Tolerability

The safety profile of triptorelin reflects the consequences of sex steroid suppression rather than direct drug toxicity. Common adverse effects include hot flashes, sexual dysfunction, fatigue, mood changes, and injection site reactions. Long-term use is associated with decreased bone mineral density, metabolic syndrome features (increased body fat, insulin resistance), cardiovascular risk factors, and cognitive changes.

The initial flare phase poses a specific clinical risk in prostate cancer patients, where a testosterone surge can cause tumor flare symptoms including bone pain, urinary obstruction, and spinal cord compression. This risk is typically managed by co-administering an antiandrogen (such as bicalutamide) for the first 2–4 weeks of therapy. GnRH antagonists (such as degarelix) provide an alternative that avoids the flare entirely.

Regulatory Status

Triptorelin is FDA-approved in multiple formulations: Trelstar (for prostate cancer) is available as 3.75 mg (1-month), 11.25 mg (3-month), and 22.5 mg (6-month) depot intramuscular injections. Triptodur (for central precocious puberty) is available as a 22.5 mg 6-month depot formulation. Additional formulations are marketed internationally under names including Decapeptyl and Gonapeptyl. It is a prescription medication requiring administration by healthcare professionals.